Doximity (NYSE:DOCS) Price Target Cut to $20.00 by Analysts at BMO Capital Markets

Doximity (NYSE:DOCS) had its price objective trimmed by BMO Capital Markets from $25.00 to $20.00 in a report released on Thursday morning, Marketbeat Ratings reports. The firm currently has a market perform rating on the stock.

Several other equities research analysts have also commented on DOCS. Piper Sandler upped their price objective on Doximity from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. JPMorgan Chase & Co. decreased their target price on Doximity from $40.00 to $33.00 and set a “neutral” rating on the stock in a research report on Friday, February 20th. Morgan Stanley decreased their target price on Doximity from $49.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday. Loop Capital set a $31.00 target price on Doximity in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $18.00 target price (down from $32.00) on shares of Doximity in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, Doximity currently has a consensus rating of “Moderate Buy” and an average price target of $30.62.

Doximity Trading Down 23.3%

Doximity stock opened at $17.94 on Thursday. Doximity has a 12 month low of $17.15 and a 12 month high of $76.51. The stock has a 50 day moving average of $24.09. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of 18.12, a PEG ratio of 1.66 and a beta of 1.36.

Doximity declared that its board has authorized a stock buyback plan on Thursday, February 5th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Doximity

In other news, Director Kira Scherer Wampler sold 9,000 shares of Doximity stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total value of $234,540.00. Following the completion of the transaction, the director owned 19,839 shares in the company, valued at approximately $517,004.34. The trade was a 31.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.77, for a total transaction of $59,502.93. Following the transaction, the insider owned 89,396 shares in the company, valued at $2,303,734.92. The trade was a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DOCS. Royal Bank of Canada raised its position in shares of Doximity by 24.2% during the 1st quarter. Royal Bank of Canada now owns 106,845 shares of the company’s stock valued at $6,200,000 after acquiring an additional 20,847 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Doximity by 0.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,978 shares of the company’s stock valued at $2,262,000 after acquiring an additional 210 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Doximity by 613.7% during the 1st quarter. NewEdge Advisors LLC now owns 6,323 shares of the company’s stock valued at $367,000 after acquiring an additional 5,437 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Doximity by 33.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 255,529 shares of the company’s stock valued at $14,828,000 after acquiring an additional 63,873 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Doximity during the 1st quarter valued at $283,000. Institutional investors and hedge funds own 87.19% of the company’s stock.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted EPS of $0.26, ahead of one analyst estimate, and revenue rose 5.1% year over year to $145.37 million, showing the core business is still growing. Doximity Earnings Report
• Positive Sentiment: Commentary around AI adoption and customer growth suggests Doximity’s platform remains engaged with clinicians, which could support longer-term monetization. Zacks Coverage
• Neutral Sentiment: The company maintained strong profitability metrics, including a 23.84% return on equity and 37.54% net margin, but those figures were overshadowed by weaker near-term outlook commentary. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Doximity missed the broader analyst consensus on EPS, which disappointed traders looking for a stronger earnings beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: Most importantly, fiscal 2027 revenue guidance came in below Wall Street expectations, reinforcing concerns that growth is slowing while AI-related investment is pressuring margins. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: Multiple analysts cut price targets after the report, including JPMorgan, Truist, BMO Capital, Mizuho, and Needham, adding to the negative sentiment around the stock. Analyst Target Cuts
• Negative Sentiment: Unusual put-option buying and an insider share sale added to the cautious tone, even though the insider transaction was part of a pre-arranged trading plan. Insider Trade Disclosure

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.